Ductal adenocarcinoma of the prostate is a rare, yet aggressive, subtype of prostate cancer that diverges in clinicopathological and genomic characteristics from the more common acinar adenocarcinoma.

Stage 1 prostate adenocarcinoma is localized, non-aggressive, and often detected through routine screenings like PSA tests and DREs. Diagnosis involves PSA levels, Gleason scores, and possibly ...

Serum biomarkers in metastatic castration-resistant prostate cancer (mCRPC) patients receiving [177Lu]Lu-PSMA-617 therapy: Post hoc analysis of a phase II clinical trial. Individual patient data (IPD) ...

The study not only enhances survival prediction but also provides novel evidence for a causal genetic link between prostate cancer and urothelial carcinoma. The team analyzed records of 6,363 prostate ...

The 2026 PSMA & Beyond conference featured a targeting the cell surface session and presentation by Dr. Rahul Aggarwal discussing DLL3 and whether target expression determines the method of targeting.

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

Chimeric RNA landscape in the Chinese population and the role of SFT2D2-TBX19 in prostate cancer progression. Risk stratification using the Decipher 22-gene genomic classifier (GC) and digital ...

Genitourinary medical oncologist Dr. Michael Morris is part of a new MSK program focused on better treatments for neuroendocrine cancers, which sometimes develop when prostate and lung cancers become ...

The 2026 PSMA & Beyond conference featured a targeting the cell surface session and presentation by Dr. Tanya Dorff discussing antibody drug conjugates and BiTEs and their role in prostate cancer. Dr.